Illumina gets $8m plus injunction from DNA sequencing suit

DNA-sequencing company Illumina has convinced a California court to bar Chinese pharma firm BGI Genomics from selling technology that infringes its genome-sequencing patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Illumina and Ariosa settle DNA patent dispute

27 May 2021 Illumina and Roche-owned Ariosa Diagnostics filed a joint stipulation asking the US Supreme Court to dismiss a case concerning the eligibility of Illumina’s DNA testing patents.

Medtech

BGI didn’t infringe one Illumina patent, fails to invalidate another

2 September 2021 The US District Court for the Northern District of California has denied an attempt by Chinese company BGI Genomics to invalidate an Illumina DNA sequencing patent in a summary judgment, leaving the dispute over infringement of another Illumina patent to be decided at trial.

More on this story

Big Pharma

Illumina and Ariosa settle DNA patent dispute

27 May 2021 Illumina and Roche-owned Ariosa Diagnostics filed a joint stipulation asking the US Supreme Court to dismiss a case concerning the eligibility of Illumina’s DNA testing patents.

Medtech

BGI didn’t infringe one Illumina patent, fails to invalidate another

More on this story

Big Pharma

Illumina and Ariosa settle DNA patent dispute

27 May 2021 Illumina and Roche-owned Ariosa Diagnostics filed a joint stipulation asking the US Supreme Court to dismiss a case concerning the eligibility of Illumina’s DNA testing patents.

Medtech

BGI didn’t infringe one Illumina patent, fails to invalidate another